Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ASP2713 in Healthy Subjects
NCT04017208Phase 1Withdrawn
- Sponsor
- Astellas Pharma
- Start
- Jul 2019
- Primary completion
- Aug 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, randomised, single-blind trial in systemic lupus erythematosus (SLE) comparing ASP2713 with Placebo (2 arms). Primary endpoints: Number of participants with Adverse Events up to 90 days, Number of participants with laboratory value abnormalities and/or adverse events related to treatment up to 90 days and 3 more. Planned start Jul 2019; status: withdrawn.
02
Drugs
ASP2713
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04017208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04017208.